CNBC
2 weeks ago
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
A pickup in the initial public offering market would be a boon to Danaher.
Latest News
Danaher had a disappointing 2024. Its path to success next year goes through Wall Street
2 weeks ago
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
6 days ago
Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise
1 week ago